Johnson & Johnson
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joaquin Duato
- Full Time Employees
- 141,700
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- One Johnson & Johnson Plaza New Brunswick NJ United States of America 08933
- IPO Date
- Jan 2, 1962
- CIK
- 0000200406
- Website
- jnj.com
- Similar Companies
- Business
- Johnson & Johnson is a global healthcare company engaged primarily in the research, development, manufacture, and sale of a broad range of pharmaceutical, medical device, and consumer health products. The company operates segments including Pharmaceuticals, Medical Devices, and Consumer Health, offering products such as prescription medicines for immunology, oncology, neuroscience, infectious diseases; orthopedic and surgical devices; and branded consumer healthcare products like Band-Aid and Listerine. Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson serves customers worldwide across multiple markets. Recent major changes include Johnson & Johnson's 2025 acquisition of neurological drug maker Intra-Cellular Therapies for approximately $14.6 billion, expanding its neuroscience portfolio. In November 2025, J&J also announced the acquisition of Halda Therapeutics for $3.05 billion to bolster its oncology pipeline with innovations targeting metastatic castration-resistant prostate cancer. The company launched new cancer therapies Vykt, Tecvayli, and Talvey targeting multiple myeloma, generating $1.3 billion in sales in the first half of 2025. Furthermore, J&J is advancing drug candidates such as nipocalimab (Imaavy) for immune-mediated disorders and Caplyta for bipolar depression. The company also plans to divest its consumer health segment, signaling a strategic shift to focus more intensively on pharmaceuticals and medical devices. Johnson & Johnson continues to pursue regulatory approvals and expand indications for key drugs including SIMPONI, STELARA, TREMFYA, and Caplyta. It projects peak sales of several pipeline candidates at approximately $5 billion each. The firm remains heavily invested in research and development across immunology, oncology, neuroscience, and autoimmune diseases, leveraging innovative technologies including adenovirus vector and mRNA platforms. Johnson & Johnson reported a 6.8% sales increase to $24 billion in Q3 2025, reflecting operational growth driven by its pharmaceutical segment. This combination of advanced product portfolios, strategic acquisitions, and selective divestitures positions Johnson & Johnson as a leading global medical and pharmaceutical company focused on delivering innovative therapeutic solutions worldwide. The company's broad geographic operations span North America, Europe, Asia-Pacific, and emerging markets, catering to diverse healthcare needs across prescription drugs, medical devices, and consumer health products.
Axiom Investment Management LLC Acquires New Holdings in Johnson & Johnson $JNJ
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline
Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?
Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About
Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals
Johnson & Johnson (JNJ) is a Top-Ranked Momentum Stock: Should You Buy?
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
Nasdaq rebounds hard as Microsoft, Apple and chipmakers rally
Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
Johnson & Johnson lowers 2026 profit forecast
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
This $3 Million Portfolio Pays $18,000 a Month From Three Income Buckets
Explainer: Can J&J finally put the talc litigation behind it?
Johnson & Johnson vs. Eli Lilly: Reliable Stability vs.
Arete Wealth Advisors LLC Acquires 11,789 Shares of Johnson & Johnson $JNJ
Amundi Has $3.28 Billion Stock Holdings in Johnson & Johnson $JNJ
How a 44-Year-Old Could Build a $9,000 Monthly Paycheck by 60 Without Maxing a 401(k)